Data as of Mar 14
| -0.20 / -1.39%|
The 6 analysts offering 12-month price forecasts for Durata Therapeutics Inc have a median target of 16.50, with a high estimate of 20.00 and a low estimate of 13.00. The median estimate represents a +16.12% increase from the last price of 14.21.
The current consensus among 6 polled investment analysts is to Buy stock in Durata Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.